Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Inbrija®▼ (Acorda Therapeutics), a levodopa powder for oral inhalation, is licensed for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
This review is older than 3 years and has been archived. To request a copy, contact nuth.nyrdtc.rxsupp@nhs.net.